tirzepatide vision loss risks in patients using popular GLP-1 medications raise concerns Zepbound and Vision Loss: An

As of August 2024, three doses of Wegovy remain in limited availability: 0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL The FDA database lists the estimated shortage duration for these doses as "TBD" (To Be Determined)

Side effects are most pronounced during dose escalation and tend to improve at each dose level as the body adapts before the next increase

PubMed CrossRef Jastreboff AM, Aronne LJ, Ahmad NN, et al

Step 5: Insert the needle through the rubber stopper of the tirzepatide vial

In clinical trials, GI side effects occur in roughly 4050% of patients on either medication, though they are typically mild to moderate and tend to improve over the first 812 weeks

The calculator assumes the stated concentration is accurate